Stay updated with breaking news from Exscientia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AI-driven discovery platform enables new way to find novel pathways as well as progress towards identifying patients who may better respond to drugs in the clinic Preclinical data highlights the
The second year of the COVID-19 pandemic saw a wave of global demand for coronavirus tests that finally reached the public markets. Diagnostics companies raised hundreds of millions of, and in some cases over a billion, dollars by pitching Wall Street on their ability to meet that need.
Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia's founder and CEO and Ben Taylor, CFO Chief Strategy Officer, will participate in fireside chats at the following investor
While the U.K. shattered its previous biotech venture capital funding record by 81% in 2021, the continental Europe saw private financing dip by about 12%. Genetic sequencing startup Oxford Nanopore and artificial intelligence drug discoverer Exscientia led the way in both VC fundraising and initial public offering proceeds.
Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Exscientia as Chief Scientist of Biologics AI. In this newly created role, she will focus on the application of artificial intelligence